Trial reportNature2017
Sterile protection against human malaria by chemoattenuated PfSPZ vaccine.
2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 255 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
255citing papers in PubMed, 2 pooled it
49.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis
NCT03952650 phase1 / phase2completednot on this mapstarted 2019, after this paper: background citation
Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falciparum Infection in Bancoumana and Surrounding Areas, Mali
Who cites it
255 citing papers in PubMed, 2 syntheses or guidelines pooled it, 408 citations in OpenAlex.
- Pooled it
- Reproducibility of malaria sporozoite challenge model in humans for evaluating efficacy of vaccines and drugs: a systematic review.BMC infectious diseases · 2021Pooled it
- Effect of controlled human Plasmodium falciparum infection on B cell subsets in individuals with different levels of malaria immunity.Medical microbiology and immunology · 2025Trial
- Safety, tolerability and immunogenicity of a condensed, multi-dose prime regimen of PfSPZ Vaccine for the prevention of Plasmodium falciparum malaria infection.Malaria journal · 2025Trial
- Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial.Nature medicine · 2025Trial
- Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.The Lancet. Infectious diseases · 2024Trial
- Immune responses associated with protection induced by chemoattenuated PfSPZ vaccine in malaria-naive Europeans.JCI insight · 2024Trial
- Implementation of a Randomized, Placebo-Controlled Trial of Live Attenuated Malaria Sporozoite Vaccines in an Indonesian Military Study Population.The American journal of tropical medicine and hygiene · 2024Trial
- Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults.The Journal of clinical investigation · 2024Trial
- Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults.The American journal of tropical medicine and hygiene · 2023Trial
- Whole sporozoite immunization with Plasmodium falciparum strain NF135 in a randomized trial.BMC medicine · 2023Trial
- A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria.Science translational medicine · 2022Trial
- The impact of Loa loa microfilaraemia on research subject retention during a whole sporozoite malaria vaccine trial in Equatorial Guinea.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2022Trial
- Trial
- Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.The Lancet. Infectious diseases · 2022Trial
- Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.Human vaccines & immunotherapeutics · 2021Trial
- Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.Nature medicine · 2021Trial
- Trial
- Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial.Nature communications · 2021Trial
- Trial
195 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 8 institutions in 3 countries.
Benjamin MordmüllerInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Güzin SuratInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Heimo LaglerInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Sumana ChakravartySanaria Inc., Rockville, Maryland 20850, USA.
Andrew S IshizukaVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, Maryland 20892, USA.
Albert LalremruataInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Markus GmeinerInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Joseph J CampoAntigen Discovery Inc., Irvine, California 92618, USA.
Meral EsenInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Adam J RubenSanaria Inc., Rockville, Maryland 20850, USA.
Jana HeldInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Carlos Lamsfus CalleInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Juliana B MengueInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Tamirat GebruInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Javier IbáñezInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Mihály SulyokInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Eric R JamesSanaria Inc., Rockville, Maryland 20850, USA.
Peter F BillingsleySanaria Inc., Rockville, Maryland 20850, USA.
K C NatashaSanaria Inc., Rockville, Maryland 20850, USA.
Anita ManojSanaria Inc., Rockville, Maryland 20850, USA.
Tooba MurshedkarSanaria Inc., Rockville, Maryland 20850, USA.
Anusha GunasekeraSanaria Inc., Rockville, Maryland 20850, USA.
Abraham G EappenSanaria Inc., Rockville, Maryland 20850, USA.
Tao LiSanaria Inc., Rockville, Maryland 20850, USA.
Richard E StaffordSanaria Inc., Rockville, Maryland 20850, USA.
Minglin LiSanaria Inc., Rockville, Maryland 20850, USA.
Phil L FelgnerDepartment of Medicine, University of California Irvine, Irvine, California 92697, USA.
Robert A SederVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, Maryland 20892, USA.
Thomas L RichieSanaria Inc., Rockville, Maryland 20850, USA.
B Kim Lee SimSanaria Inc., Rockville, Maryland 20850, USA.
Stephen L HoffmanSanaria Inc., Rockville, Maryland 20850, USA.
Peter G KremsnerInstitute of Tropical Medicine, University of Tübingen and German Center for Infection Research, partner site Tübingen, 72074 Tübingen, Germany.
Sanaria · USGerman Center for Infection Research · DEUniversity of Tübingen · DENational Institute of Allergy and Infectious Diseases · USProtein Potential (United States) · USAntigen Discovery (United States) · USMedical University of Vienna · ATUniversity of California, Irvine · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MDevelopment of Pre-Erythrocytic Malaria Vaccines and antibodiesZIAAI005107 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SEDER, ROBERT A · 2010 to 2025
$20.7MPlasmodium Falciparum Whole Sporozoite Malaria VaccineR44AI055229 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2005 to 2015
$10.0MUniversal Attenuated Sporozoite Vaccine and Challenge SystemR44AI058375 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2006 to 2018
$9.9MMedical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6MAutomating mosquito microdissection for a malaria PfSPZ vaccineR44AI134500 · NIAID · SANARIA, INC. · PI CHAKRAVARTY, SUMANA, HOFFMAN, STEPHEN LEV · 2017 to 2023
$5.9MProtective biomarkers for the development of vaccines against malariaR44AI066791 · NIAID · IMMPORT THERAPEUTICS, INC. · PI FELGNER, PHILIP LOUIS · 2012 to 2014
$2.3MAseptic, purified attenuated sporozoite malaria vaccineR43AI058375 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2004 to 2005
$600kAttenuated Malaria Sporozoite VaccineR43AI055229 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2003 to 2004
$544kNIAID NIH HHS 5R44AI058375NIAID NIH HHS R43 AI055229NIAID NIH HHS R43 AI058375NIAID NIH HHS R44 AI055229NIAID NIH HHS R44 AI058375NIAID NIH HHS R44 AI066791NIAID NIH HHS R44 AI134500NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM145449
Abstract
A highly protective malaria vaccine would greatly facilitate the prevention and elimination of malaria and containment of drug-resistant parasites. A high level (more than 90%) of protection against malaria in humans has previously been achieved only by immunization with radiation-attenuated Plasmodium falciparum (Pf) sporozoites (PfSPZ) inoculated by mosquitoes; by intravenous injection of aseptic, purified, radiation-attenuated, cryopreserved PfSPZ ('PfSPZ Vaccine'); or by infectious PfSPZ inoculated by mosquitoes to volunteers taking chloroquine or mefloquine (chemoprophylaxis with sporozoites). We assessed immunization by direct venous inoculation of aseptic, purified, cryopreserved, non-irradiated PfSPZ ('PfSPZ Challenge') to malaria-naive, healthy adult volunteers taking chloroquine for antimalarial chemoprophylaxis (vaccine approach denoted as PfSPZ-CVac). Three doses of 5.12 × 10
Indexed as
AdolescentAdultAntibodies, ProtozoanChloroquineDouble-Blind MethodHealthy VolunteersHumansImmunologic MemoryMalaria, FalciparumMalaria VaccinesMiddle AgedPlasmodium falciparumSporozoitesTime FactorsT-LymphocytesVaccines, AttenuatedAntibodies, ProtozoanChloroquineMalaria VaccinesVaccines, Attenuated
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02115516ClinicalTrials.gov
NCT03952650ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.